[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657605":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":44,"studyPopulation":44,"armGroups":52,"interventions":69,"overallOfficials":82,"centralContacts":87,"locations":97,"responsibleParty":189,"collaborators":192,"id":195,"slug":196,"hasResults":197,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":197,"sex":203,"minAge":204,"maxAge":44,"enrollmentInfo":205,"targetDuration":44,"studyType":208,"phases":209,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":221,"whyStopped":44,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients with mRS 0-1 at 90 days","Percentage of participants achieving modified Rankin Scale (mRS) score 0 or 1 at 90 days after randomization.","90 days after randomization",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"mRS score at 90 days","Modified Rankin Scale (mRS) score assessed at 90 days after randomization.",{"measure":18,"description":19,"timeFrame":12},"EQ-5D-5L score at 90 days","EQ-5D-5L questionnaire score assessed at 90 days after randomization.",{"measure":21,"description":22,"timeFrame":12},"Proportion of patients with mRS 0-2 at 90 days","Percentage of participants achieving modified Rankin Scale (mRS) score 0 to 2 at 90 days after randomization.",{"measure":24,"description":25,"timeFrame":12},"Proportion of patients with mRS 0-3 at 90 days","Percentage of participants achieving modified Rankin Scale (mRS) score 0 to 3 at 90 days after randomization.",{"measure":27,"description":28,"timeFrame":29},"Proportion of early neurological improvement","Percentage of participants with early neurological improvement, defined as ≥30% reduction in NIHSS score at 48 hours post-randomization compared with the NIHSS score at randomization.","48 hours after randomization",[31,35,38],{"measure":32,"description":33,"timeFrame":34},"Incidence of symptomatic intracranial hemorrhage (sICH) within 48 hours","Proportion of participants with symptomatic intracranial hemorrhage (sICH) within 48 hours after randomization, defined by the Heidelberg criteria.","Within 48 hours after randomization",{"measure":36,"description":37,"timeFrame":34},"Incidence of any intracranial hemorrhage (any ICH) within 48 hours","Proportion of participants with any intracranial hemorrhage (any ICH) within 48 hours after randomization.",{"measure":39,"description":40,"timeFrame":12},"90-day mortality","Proportion of participants who die within 90 days after randomization.",{"allocation":42,"interventionModel":43,"interventionModelDescription":44,"primaryPurpose":45,"observationalModel":44,"timePerspective":44,"maskingInfo":46},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":47,"maskingDescription":48,"whoMasked":49},"DOUBLE","Participants and treating investigators are unblinded (open-label). Outcome assessors for primary endpoint are blinded to treatment assignment.",[50,51],"CARE_PROVIDER","OUTCOMES_ASSESSOR",[53,59,63],{"label":54,"type":55,"description":56,"interventionNames":57},"Arm A: Tirofiban 24-hour group","EXPERIMENTAL","Arm A: Patients receive tirofiban for 24 hours after intravenous thrombolysis.",[58],"Drug: Tirofiban Injection",{"label":60,"type":55,"description":61,"interventionNames":62},"Arm B: Tirofiban 48-hour group","Arm B: Patients receive tirofiban for 48 hours after intravenous thrombolysis.",[58],{"label":64,"type":65,"description":66,"interventionNames":67},"Arm C: Standard care control group","ACTIVE_COMPARATOR","No tirofiban is administered after intravenous thrombolysis.",[68],"Other: No Interventions",[70,75,78],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":44},"DRUG","Tirofiban Injection","Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 24 hours. The dosage regimen follows the trial protocol.",[54],{"type":71,"name":72,"description":76,"armGroupLabels":77,"otherNames":44},"Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 48 hours. The dosage regimen follows the trial protocol.",[60],{"type":6,"name":79,"description":80,"armGroupLabels":81,"otherNames":44},"No Interventions","No tirofiban will be administered after intravenous thrombolysis. Patients receive routine standard clinical management according to hospital guidelines.",[64],[83],{"name":84,"affiliation":85,"role":86},"zhongming qiu","Xinqiao Hospital of the Army Medical University","PRINCIPAL_INVESTIGATOR",[88,93],{"name":89,"role":90,"phone":91,"phoneExt":44,"email":92},"Guoyong Zeng, doctor","CONTACT","+8613507079530","hsyygy@126.com",{"name":94,"role":90,"phone":95,"phoneExt":44,"email":96},"Fan Zhang, doctor","+8618970148470","zhappy0066@126.com",[98,111,121,131,141,147,156,161,169,179],{"facility":99,"status":44,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":44},"Taihe County People's Hospital","Fuyang","Anhui","236600","China","CN",{"type":106,"coordinates":107},"Point",[108,109],115.81667,32.9,{"lat":109,"lon":108},{"facility":112,"status":44,"city":113,"state":114,"zip":115,"country":103,"countryCode":104,"cosmosGeoPoint":116,"geoPoint":120,"contacts":44},"Longyan First Hospital of Fujian Medical University","Longyan","Fujian","364000",{"type":106,"coordinates":117},[118,119],117.01775,25.07485,{"lat":119,"lon":118},{"facility":122,"status":44,"city":123,"state":124,"zip":125,"country":103,"countryCode":104,"cosmosGeoPoint":126,"geoPoint":130,"contacts":44},"Xiangtan Central Hospital (The Affiliated Hospital of Hunan University)","Xiangtan","Hunan","411100",{"type":106,"coordinates":127},[128,129],112.9,27.85,{"lat":129,"lon":128},{"facility":132,"status":44,"city":133,"state":134,"zip":135,"country":103,"countryCode":104,"cosmosGeoPoint":136,"geoPoint":140,"contacts":44},"Ganzhou People's Hospital","Ganzhou","Jiangxi","341000",{"type":106,"coordinates":137},[138,139],114.9326,25.84664,{"lat":139,"lon":138},{"facility":142,"status":44,"city":133,"state":134,"zip":143,"country":103,"countryCode":104,"cosmosGeoPoint":144,"geoPoint":146,"contacts":44},"Xingguo People's Hospital, Xinguo Hospital of Gannan Medical University","342414",{"type":106,"coordinates":145},[138,139],{"lat":139,"lon":138},{"facility":148,"status":44,"city":149,"state":134,"zip":150,"country":103,"countryCode":104,"cosmosGeoPoint":151,"geoPoint":155,"contacts":44},"Jingdezhen First People's Hospital","Jingdezhen","333000",{"type":106,"coordinates":152},[153,154],117.20789,29.2947,{"lat":154,"lon":153},{"facility":157,"status":44,"city":149,"state":134,"zip":135,"country":103,"countryCode":104,"cosmosGeoPoint":158,"geoPoint":160,"contacts":44},"The First People's Hospital of Jingdezhen City",{"type":106,"coordinates":159},[153,154],{"lat":154,"lon":153},{"facility":162,"status":44,"city":163,"state":134,"zip":44,"country":103,"countryCode":104,"cosmosGeoPoint":164,"geoPoint":168,"contacts":44},"Jiujiang First People's Hospital","Jiujiang",{"type":106,"coordinates":165},[166,167],116.00206,29.70475,{"lat":167,"lon":166},{"facility":170,"status":44,"city":171,"state":172,"zip":173,"country":103,"countryCode":104,"cosmosGeoPoint":174,"geoPoint":178,"contacts":44},"Dalian Central Hospital","Dalian","Liaoning","116000",{"type":106,"coordinates":175},[176,177],121.60222,38.91222,{"lat":177,"lon":176},{"facility":180,"status":44,"city":181,"state":182,"zip":183,"country":103,"countryCode":104,"cosmosGeoPoint":184,"geoPoint":188,"contacts":44},"The First People's Hospital of Mianyang (Mianyang 404 Hospital)","Mianyang","Sichuan","621000",{"type":106,"coordinates":185},[186,187],104.68168,31.46784,{"lat":187,"lon":186},{"type":86,"investigatorFullName":190,"investigatorTitle":191,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Zhongming Qiu","Professor",[193],{"name":194,"class":6},"The Affiliated Ganzhou Hospital of Nanchang University","100657605","phase-2-a-multicenter-three-arm-open-label-endpoint-blinded-randomized-controlled-trial-to-evaluate-the-optimal-duration-of-early-tirofiban-after-intravenous-thrombolysis-in-acute-ischemic-stroke-100657605",false,"NCT07842185","A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke","A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Infusion Duration of Early Tirofiban Treatment After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke (INSTANT-2)","INSTANT-2","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of acute ischemic stroke meeting the diagnostic criteria from Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023, and the patient has received intravenous thrombolysis with tenecteplase, alteplase or reteplase.\n3. Disabling stroke remains at 2-24 hours after completion of intravenous thrombolysis. Disabling stroke is defined as NIHSS score ≥ 4, or single limb motor subscore ≥ 2.\n4. Written informed consent is obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI after intravenous thrombolysis and prior to randomization.\n2. CTA\u002FMRA\u002FDSA demonstrates occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery, anterior cerebral artery, or vertebrobasilar artery.\n3. History of atrial fibrillation or suspected cardioembolic stroke. Platelet count \\\u003C100×10⁹\u002FL on routine blood test.\n4. Renal insufficiency with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin.\n5. Pregnant or breastfeeding women.\n6. Pre-existing neurological or psychiatric disorders that interfere with neurological function assessment.\n7. History of bleeding disorders, severe cardiac, hepatic or renal disease, or sepsis.\n8. Brain tumor with mass effect on imaging (excluding small meningioma). Intracranial aneurysm or arteriovenous malformation (AVM).\n9. Advanced illness with life expectancy less than 6 months.\n10. Current participation in another clinical trial.\n11. Other conditions deemed unsuitable for enrollment by the investigator.","ALL","18 Years",{"count":206,"type":207},1482,"ESTIMATED","INTERVENTIONAL",[210,211],"PHASE2","PHASE3","Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular recanalization. The reocclusion rate ranges from 14% to 34%, and many patients are left with residual neurological deficits. Early antiplatelet therapy initiated after thrombolysis may sustain persistent reperfusion and improve prognosis. However, current guidelines generally recommend delaying antiplatelet treatment until 24 hours post-thrombolysis due to bleeding risks, and direct evidence for the optimal initiation timing remains lacking. Tirofiban is a rapidly acting, short-half-life, reversible glycoprotein IIb\u002FIIIa receptor antagonist. Previous studies indicate its potential benefits and acceptable safety when administered after intravenous thrombolysis.\n\nThis is a multicenter, three-arm, open-label, endpoint-blinded randomized controlled trial. A total of 1482 non-cardioembolic patients without large or medium vessel occlusion and with residual neurological deficits (NIHSS ≥4) after thrombolysis will be enrolled. Participants will be randomly allocated to the tirofiban 24-hour group, tirofiban 48-hour group, or blank control group. The primary outcome is the proportion of patients with excellent functional outcome defined as modified Rankin Scale (mRS) score 0-1 at 90 days. Symptomatic intracranial hemorrhage and neurological outcomes will also be evaluated. The study aims to determine the optimal duration of tirofiban treatment after thrombolysis and provide high-level evidence for precise interventions in the acute phase of stroke.",[214],"Acute Ischemic Stroke",[216,217,218,219,220],"Intravenous Thrombolysis","acute ischemic stroke","tirofiban","alteplase","tenecteplase","NOT_YET_RECRUITING","2026-09-20",{"date":224,"type":225},"2026-09-25","ACTUAL",{"date":227,"type":207},"2026-11-19",{"date":229,"type":207},"2031-05-08",{"name":5,"class":6},10]